A Phase 1 interventional study of GC1123 in Mucopolysaccharidosis II and Hunter Syndrome, sponsored by GC Biopharma Corp. Active, not recruiting at 3 sites in Korea, Republic of. Open to participants aged 18 Months to 18 Years. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by GC Biopharma Corp · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intracerebroventricular GC1123 in patients with MPS Ⅱ who have central nervous system involvement and are receiving treatment with intravenous drug
This study is designed as prospective, open-label, phase I and extension study. Safety, tolerability, pharmacokinetic, and pharmacodynamic properties of repeat-dose treatment of ICV-administered investigational product will be studied in patients undergoing standard treatments.
Patients will undergo cerebrospinal fluid (CSF) reservoir device implantation surgery on their scalps, and the reservoirs will be used to administer GC1123 to the cerebral ventricles monthly (every 28 days). The planned administering dose is 30 mg. After the 2nd dose on the 6th patient, Data and Safety Monitoring Boards (DSMB) will evaluate the safety and tolerability data of GC1123. The planned duration of the sutdy is total about 2 years (phase I and extension)
77 studies on the registry are indexed under Mucopolysaccharidosis II; 8 are open to participants now.
This study's planned enrollment of 12 is below the median of 22 across 48 interventional studies indexed under Mucopolysaccharidosis II.
Browse Mucopolysaccharidosis II studies →GC Biopharma Corp is the lead sponsor of 16 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
30 mg of IP will be administered every 28 days for all enrolled patients
Biological: GC1123
ICV-administered Hunterase, Idursulfase-ß
Incidence and frequency of serious adverse events (SAEs)
Incidence and frequency of serious adverse events (SAEs) after administration of ICV-Hunterase (GC1123)
Time frame: Every 28 days from Week 1 through study completion (about 110 weeks)
Frequency and characteristics (severity, outcome, etc.) of adverse events
Frequency and characteristics (severity, outcome, etc.) of adverse events after administration of ICV-Hunterase (GC1123)
Time frame: Every 28 days from Week 1 through study completion (about 110 weeks)
Presence of clinically significant abnormal echocardiography results
Presence of clinically significant abnormal echocardiography results after administration of ICV-Hunterase (GC1123); phase I only
Time frame: Week 1 to Phase I study completion (about 26 weeks)
Pharmacokinetic (PK) parameters - Cmax
Pharmacokinetic (PK) parameters of ICV-Hunterase (GC1123) in serum and CSF
Time frame: Week 2 to Week 22
Pharmacokinetic (PK) parameters - Tmax
Pharmacokinetic (PK) parameters of ICV-Hunterase (GC1123) in serum and CSF
Time frame: Week 2 to Week 22
Pharmacokinetic (PK) parameters - AUClast
Pharmacokinetic (PK) parameters of ICV-Hunterase (GC1123) in serum and CSF
Time frame: Week 2 to Week 22
Pharmacokinetic (PK) parameters - AUCinf
Pharmacokinetic (PK) parameters of ICV-Hunterase (GC1123) in serum and CSF
Time frame: Week 2 to Week 22
Pharmacokinetic (PK) parameters - t1/2
Pharmacokinetic (PK) parameters of ICV-Hunterase (GC1123) in serum and CSF
Time frame: Week 2 to Week 22
Pharmacokinetic (PK) parameters - CL/F (or CL)
Pharmacokinetic (PK) parameters of ICV-Hunterase (GC1123) in serum and CSF
Time frame: Week 2 to Week 22
Pharmacokinetic (PK) parameters - Vd/F (or Vd)
Pharmacokinetic (PK) parameters of ICV-Hunterase (GC1123) in serum and CSF
Time frame: Week 2 to Week 22
Pharmacokinetic (PK) parameters - Bioavailability (F)
Pharmacokinetic (PK) parameters of ICV-Hunterase (GC1123) in serum and CSF
Time frame: Week 2 to Week 22
Pharmacodynamic (PD) parameters - Heparan Sulfate (HS) in CSF
Pharmacodynamic (PD) parameters of ICV-Hunterase (GC1123)
Time frame: Every 28 days from Week 1 through study completion (about 110 weeks)
Pharmacodynamic (PD) parameters - Heparan Sulfate (HS) in serum
Pharmacodynamic (PD) parameters of ICV-Hunterase (GC1123)
Time frame: Every 28 days from Week 1 through study completion (about 110 weeks)
Pharmacodynamic (PD) parameters - Urine Glycosaminoglycan (GAG)
Pharmacodynamic (PD) parameters of ICV-Hunterase (GC1123)
Time frame: Every 28 days from Week 1 through study completion (about 110 weeks)
Presence of anti-drug antibodies (ADAs)
Presence of anti-drug antibodies (ADAs) in CSF and serum, and neutralizing antibodies of ICV-Hunterase (GC1123)
Time frame: Approximately every 6 months (Week 2 [baseline], Week 18, Week 26, Week 54, Week 82, Week 110)
Development Function assessed by Bayley Scales of Infant and Toddler Development-III and/or Kaufman Assessment Battery for Children-II (BSID-III/KABC-II)
All children will be tested for BSID-III, and children over the age of 3 will be also tested for KABC-II.
Time frame: Approximately every 6 months (Week 1 [baseline], Week 26, Week 54, Week 82, Week 110)
Adaptive Function assessed by Vineland Adaptive Behavior Scales 2nd Ed. (VABS-II)
Children under the age of 19 years will be tested for VABS-II.
Time frame: Approximately every 6 months (Week 1 [baseline], Week 26, Week 54, Week 82, Week 110)
Quality of Life (Survey) assessed by Infant and Toddler Quality of Life Questionnaire (ITQOL) and/or Childhood Health Questionnaire parent form (CHQ-PF50)
Children from the age of 2 months to 5 years will be tested for ITQOL, and children over the age of 5 will be tested for CHQ-PF50. The test performed during screening will be continued to be performed for each patient throughout the study period.
Time frame: Approximately every 6 months (Week 1 [baseline], Week 26, Week 54, Week 82, Week 110)
Liver and Spleen volume
Liver and Spleen volume measured by MRI -phase I only
Time frame: Week 1 to phase I study completion (about 26 weeks)
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2022 (actual). Primary completion is estimated for Jun 2027, 57 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.